

氏名	所属	職名	取得学位	専門分野	主な論文・著作・業績
西谷 直之	臨床薬学講座 情報薬科学分野	教授	博士（薬学）	創薬科学 腫瘍治療学 ケミカルバイオロジー	①Ujiie, H., Sakyo, T., Oya, K., Sugawara, Y., Ota, M., Yonezawa, H., Nishiya, N., Machine Learning–Driven Integration of Cancer Cell Phenotypes Predicts Cisplatin Sensitivity, Cancer Medicine 14, no. 22 (2025): e71373, ②Yonezawa, H., Ikeda, A., Takahashi, R., Endo, H., Sugawara, Y., Goto, M., Kanno, M., Ogawa, S., Nakamura, K., Ujiie, H., Iwatsuki, M., Hirose, T., Sunazuka, T., Uehara, Y., Nishiya, N. : Ivermectin represses Wnt/ β -catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases./ iScience. 25(3):103912 (2022) ③Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu, K., Sakyo, T., Abe, M., Yonezawa, H., Ishibashi, F., Matsuura, M., Tomida, A., Seimiya, H., Yamori, T., Iwao, M., Uehara, Y. : Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal Growth Factor Receptor. / Cancer Sci., 112: 1963–1974 (2021) ④文部科学省科学研究費補助金「課題名：生体高分子認識構造 α -solenoidを標的とした中分子創薬の基盤構築」2024～2027年 ⑤特許 第7090252号「第四世代EGFRチロシンキナーゼ阻害剤」令和4年6月16日
佐京 智子	臨床薬学講座 情報薬科学分野	助教	博士（医学）	細胞生物学 病態医化学 腫瘍生物学	①Haruki Ujiie, Tomoko Sakyo, Konomi Oya, Yuto Sugawara, Miyu Ota, Honami Yonezawa, Naoyuki Nishiya.,Machine Learning-Driven Integration of Cancer Cell Phenotypes Predicts Cisplatin Sensitivity. / Cancer Med., e71373112: doi: 10.1002/cam4.71373. (2025) ②Yonezawa, H., Sugawara, A., Sakyo, T., Uehara, Y., Kawano, T., Nishiya, N. : IMU1003, an atrarate derivative, inhibits Wnt/ β -catenin signaling. / Biochem. Biophys. Res. Commun. 532: 440-445 (2020) ③ Watanabe, M., Naraba, H., Sakyo, T., Kitagawa, T. : DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. / Mol Cancer Res.8, 1547-57 (2010) ④ Sakyo, T., Naraba, H., Teraoka, H., and Kitagawa, T. : The intrinsic structure of glucose transporter isoforms Glut1 and Glut3 regulates their differential distribution to detergent-resistant membrane domains in non-polarized mammalian cells. / FEBS Journal, vol. 274, 2843-2853 (2007) ⑤ Sakyo, T., and Kitagawa, T. : Differential localization of glucose transporter isoformes in non-polarized mammalian cells: Distribution of GLUT1 but not GLUT3 to detergent-resistant membrane domains. / Biochimica Biophysica Acta(BBA)-Biomembranes, 1567: 165-175 (2002)

氏家 悠貴	臨床薬学講座 情報薬科学分野	助教	博士（薬学）	医療薬学 がん化学療法	①Ujiie, H., Sakyo, T., Oya, K., Sugawara, Y., Ota, M., Yonezawa, H., Nishiya, N., Machine Learning–Driven Integration of Cancer Cell Phenotypes Predicts Cisplatin Sensitivity, Cancer Medicine 14, no. 22 (2025): e71373, https://doi.org/10.1002/cam4.71373. ②Ujiie, H., Nishiya, N., Yamamoto, A. , Takada, T., Onodera, M., Sasaki, A., Oikawa, T., Dexamethasone reduces cisplatin-induced hair cell damage by inducing cisplatin resistance through metallothionein-2. / Cancer Chemother Pharmacol. doi: 10.1007/s00280-024-04706-z. (2024) ③Takahashi, H., Saito, Y,. Sugawara, K,. Sato, M,. Tairabune, T,. Ujiie, H,. Asaka, J,. Kudo, K. : Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study. /CancerChemotherapy and Pharmacology. 93(4):319-328 (2024). ④氏家悠貴（著者）,中原保裕（監修）,今日の臨床サポート,がん免疫療法（薬理）,エルゼビア・ジャパン(2023) https://clinicalsup.jp/jpoc/contentpage.aspx?diseaseid=2283. ⑤令和8-10年度科学研究費補助金（若手研究）「化学療法抵抗性バイオマーカーSTK32Aキナーゼを標的とした耐性克服戦略」
-------	-------------------	----	--------	----------------	--